Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer Clinical Trial

Official title:

a Pilot Study to Explore the Efficacy and Safety of Dasatinib Combined With Quercetin to Reverse Chemotherapy Resistance in Triple Negative Breast Cancer.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06355037
• Other study ID #: B2024.1.30
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 10, 2024
• Est. completion date: January 31, 2025

Study information

• Verified date: April 2024
• Source: Fudan University
• Contact: Zhimin Shao, MD, PhD
• Phone: +8664175590
• Email: zhimingshao[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.

Description:

This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy. Chemotherapy is the backbone drug for TNBC. How to reverse chemotherapy resistance or how to increase the sensitivity of chemotherapy efficacy, has become an urgent clinical problem to be solved. Our preclinical studies have demonstrated that the combination of dasatinib and quercetin with chemotherapy can effectively eliminate chemotherapy-induced senescent fibroblasts, decrease the proliferation rate of disseminated tumor cells, and ultimately lead to a significant reduction in metastasis and recurrence, thereby enhancing the efficacy of chemotherapy. Based on preclinical studies, the investigators designed this study to enroll mTNBC patients who have progressed during or following chemotherapy, and to explore the efficacy of combined treatment of dasatinib, quercetin with chemotherapy at a clinical level, providing new strategies of combined treatment for TNBC patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: January 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• ECOG Performance Status of 0, 1

• Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)

• Radiologic/objective evidence of recurrence or disease progression after chemotherapy for metastatic breast cancer (MBC)

• Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm

• Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)

• have the cognitive ability to understand the protocol and be willing to participate and to be followed up

Exclusion Criteria:

• Symptomatic, untreated, or actively progressing CNS metastases

• Active or history of autoimmune disease or immune deficiency

• Significant cardiovascular disease

• History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death

• Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic surgery excluded) within 3 weeks prior to initiation of study treatment.

• Pregnancy or breastfeeding, or intention of becoming pregnant during the study

• History of allergies to the drug components of this trial

• Patients who have been using oral steroid hormones for a long time will need to stop for 4 weeks if they have used them occasionally in the past

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Neoplasms
• Triple-negative Breast Cancer

Intervention

Drug:
• Quercetin
quercetin 1000mg d1-d3, qw
• Dasatinib
Dasatinib 100mg d1-d3, qw
• Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)		Baseline until disease progression or loss of clinical benefit, assessed up to 6 months
Secondary	Disease Control Rate (DCR)		Baseline through end of study, assessed up to 6 months
Secondary	Progression Free Survival (PFS)		Randomization to death from any cause, through the end of study,assessed up to 6 months
Secondary	Safety and treatment-related AEs		Randomization to death from any cause, through the end of study,assessed up to 12 months
Secondary	Biomarker analysis1	the pre- and post-treatment levels of age-related secretory factors and neutrophil extracellular traps in serum and lung puncture samples.	Baseline until disease progression or loss of clinical benefit, assessed up to 6 months
Secondary	Biomarker analysis2	Immunohistochemical staining of tissue sections before and after treatment including number of senescent fibroblasts, number and area of neutrophil extracellular traps.	Baseline until disease progression or loss of clinical benefit, assessed up to 6 months